Recent Trends in Nanoparticles Based Drug Delivery for Tuberculosis Treatment

Chandni Pachouri*, Bharat Patel, Sandhya Shroti, Sandeep Shukla and Archna Pandey

Department of Chemistry, Dr. Hari Singh Gour Central University Sagar, MP, India

Abstract

Current treatment therapeutic approach for tuberculosis is the administration of first line drugs in the form of tablets and capsules for 4-6 months however; this approach leads to sever adverse effect. Therefore, present study was designed to achieving local and sustained targeting of ant tuberculosis drugs in order to reduce dose and frequency. Nanoparticles (NPs) have been found to be potential targeted and controlled release drug delivery systems. Various drugs can be loaded in the NPs to achieve targeted delivery. Nanoparticles of antituberculosis drugs are generally prepared by using chitosan and PLGA polymer. Nanoparticles of Chitosan being biodegradable, biocompatible, less toxic and easy to prepare, are an effective and potential tool for drug delivery. The selection of a nanoencapsulation technique should consider drug property, nanoparticle quality, scale-up feasibility, manufacturing costs, personnel safety, environmental impact, waste disposal, and the like. In recent years, there have been a plethora of nanoengineering approaches for the development of poly (lactide-co-glycolide) (PLGA) nanoparticulate carrier systems. However, overlooking the multifaceted issues in the preparation and characterization of PLGA-based nanoparticles. Relevant information might be helpful to those who prepare and develop nanoparticles of ant tuberculosis drugs that meet their specific demands.

Keywords
Biodegradable, Drug delivery, Nanoparticles, Nanoencapsulation

Introduction

In spite of the absolute number of incident TB cases falling globally, tuberculosis (TB) continues to be the leading cause of mortality worldwide and has also been considered to be an occupational disease in the health care setup [1]. One of the major problems in the current treatment of tuberculosis is the noncompliance to prescribed regimens, primarily because treatment of TB involves continuous, frequent multiple drug dosing. Adherence to treatment and the outcome of therapy could be improved with the introduction of long-duration drug formulations releasing the antitubercular agents in a slow and sustained manner [2]. Worldwide, around 10 million people fall ill with tuberculosis (TB) each year. TB is one of the top 10 causes of death, and the leading cause from a single infectious agent (Mycobacterium tuberculosis), ranking above HIV/AIDS. The disease can affect anyone anywhere, but most people who develop TB (about 90%) are adults, the male:female ratio is 2:1, and case rates at national level vary from less than 50 to more than 5000 per 1 million population per year. Almost 90% of cases each year are in 30 high TB burden countries. Globally, an estimated 1.7 billion people are infected with M. tuberculosis and are thus at risk of developing the disease [3]. With a timely diagnosis and treatment Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis, a microorganism that usually attacks not only lungs but also other parts of the body such as spine, kidney, and brain [4].

Available treatment

The current antibiotic treatment of active TB consists in the administration of the first-line drugs isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and ethambutol (EMB) for 2 months, followed by RIF and INH for 4 months. Poor adherence to long-term therapy increases the number of patients harboring multidrug-
resistant (MDR) *M. tuberculosis* strains (i.e., resistant at least to INH and RIF) and extensively drug-resistant strains (i.e., MDR strains resistant to any fluoroquinolone (FQ) and to at least one injectable second-line drug, kanamycin, amikacin (AK), or capreomycin (CP)) [5,6].

Besides active TB, an estimated 2 billion people in the world have latent TB infection (LTBI) i.e., they harbor *M. tuberculosis* in a non-replicating (NR) (dormant) stage in their tissues, with 10% of persons reactivating to active TB lifetime [4]. As similar to active TB, the treatment of decades that latent TB is also very long, including 9 months of INH or 3 months of RFP plus INH [7].

### Rationale of anti-TB treatment

During the two span the discovery of streptomycin in 1943 and that of rifampicin in 1963, practically all the active drugs against *M. tuberculosis* were discovered, making it very easy to cure TB [8,9].

Furthermore, during those years, the fundamental basis of TB treatment was defined based on the analysis of multiple randomized clinical trials (RCTs), the fundamentals of which are still entirely valid today [10]: 1) Combining different effective drugs to avoid the selection of resistant *M. tuberculosis* strains; and 2) Ensuring that treatment is long enough to sterilize the tissues infected with *M. tuberculosis* and, therefore, prevent relapse [11,12].

It is currently accepted that any anti-TB treatment should include at least four drugs that are likely to be effective; of which at least two are essential or core drugs and two are companion drugs. The core drugs are those with the capacity to kill *M. tuberculosis* in any of its metabolic phases. In contrast, the role of the companion drugs is to accompany the essential core ones, protecting their action and avoiding resistance selection. Among the core drugs, one should have good bactericidal activity and the other should present good sterilizing activity. These two drugs should ideally be maintained for the whole treatment duration [13]. The bactericidal drugs quickly reduce the bulk of the rapid multiplying bacilli, decreasing infectiousness and avoiding the disease’s progression. The sterilizing drugs attack the dormant and semi-dormant bacillus populations, allowing cure while preventing relapse. The drugs with the best sterilizing activity are those that may reduce the duration of the treatment. The two companion drugs are no longer necessary after bacteriological conversion [14].

### Classification of anti-TB drugs

To build an appropriate anti-TB regimen TB, WHO recommends a stepwise process based on five groups for MDR/XDR-of anti-TB drugs. The stepwise process leading to the adequate design of a regimen suitable to cure MDR/XDR-TB patients is summarized in Table 1.

The choice of the drugs is based on their efficacy and toxicity, where group 1 includes first-line drugs and group 2-5 include SLDs. Group 5 includes the drugs with potentially limited efficacy or limited clinical evidence. Length of TB treatment:- Minimum length of treatment is 21 months, divided as follows: Intensive phase: 6 months and ≥ 4 months after culture conversion; longer if three effective drugs are not available during the continuation phase Continuation phase [15,16].

### Group 1

All potentially effective group 1 drugs should be included in the regimen, considering that isoniazid, rifampicin and pyrazinamide are core drugs, and ethambutol is a companion drug. High-dose isoniazid should be added to an MDR/XDR-TB regimen when the katG mutation is not documented by the Genotype line probe assay (Quest Diagnostics, Madison, NJ, USA) but it should not be counted as one of the four active drugs. Pyrazinamide should always be used, although its drug susceptibility test is unreliable, but it also should not be considered as one of the four active drugs [8,17].

### Group 2

According to the current WHO classification, group 2 includes the injectable SLDs and group 3 includes the fluoroquinolones. The fluoroquinolones (particularly the later-generation fluoroquinolones, like high-dose levofloxacin or moxifloxacin [7] are core drugs, with bactericidal and sterilizing activity, as well as a good safety profile, and their use predicts a favorable outcome in MDR-TB treatment. Conversely, the injectable SLDs have only bactericidal activity (not sterilizing) and their safety profile is clearly worse [9,10].

### Group 3

If we include the fluoroquinolones in group 2, the question is what drugs should comprise group...
Nanoparticles and tuberculosis

Nanobead delivery has a remarkable feature of slow, sustained, and controlled release from a biodegradable particle. Different animal models have been tried out to develop an antibiotic therapy based on polymer technology against *M. tuberculosis* but unfortunately not a single model stands up to the expectation or imitates all the features of human TB [23].

The sizes of nanoparticles which are defined as submicron (< 1 um) colloidal particles are used as drug delivery vehicles. For therapeutic purposes, drugs can be covalently embedded to the particle surface or can be incorporated in the matrix of the particle. Nanoparticles comprise biocompatible and biodegradable materials such as polymers, which can be either natural (e.g., gelatin and albumin), synthetic (e.g., polylactides and polyalkylcyanoacrylates), or solid lipids (SLNR and NLCR) [24]. Nanoparticles are taken up more efficiently by cells than larger molecules which make them a promising transport and delivery system. These carriers are adapted to enable controlled, slow, and persistent drug release from the matrix [25]. Several methods have been discussed explicitly in several reviews for preparation and characterization of nanoparticles. Below are the advantages of nanoparticle-based drug delivery system for treatment of tuberculosis:

1) High constancy/longer time period,
2) High carrier ability; that is, multiple drugs can be encapsulated in the matrix,
3) Less side effects compared to conventional drugs,
4) Increased bioavailability (slow, sustained, and controlled drug release),
5) Viability of various routes of administration like oral delivery and inhalation,
6) Minimal side effects and improved compliance.

### Preparation Methods of Nanoparticles

Polymeric nanoparticles have been synthesized by several methods depending on the requirements of their application and the physicochemical characteristics of the drug. The choice of the most suitable method plays a vital role in order to obtain PNPs with the desired properties for a particular application [26].

#### Classical emulsion-templated nanoencapsulation technique

**Water-in-Oil (w/o) emulsion phase separation:**

An aqueous drug solution is emulsified in an organic solution (e.g., methylene chloride) in which PLGA is
dissolved. A phase inducer (e.g., silicone oil, vegetable oil, or mineral oil), being an anti-solvent for PLGA but a solvent for the organic solvent, is added to the w/o emulsion to induce coacervation. Formation of coacervates around the inner aqueous phase and their fusion generate embryonic PLGA particulates. To harden them, the suspension is further treated with an organic solvent (e.g., heptane), which is a non-solvent for PLGA but a solvent for the dispersed solvent and the phase inducer. EP 2131815 describes the principle of this process and its application in encapsulation of various water-soluble drugs into PLGA particles [27]. This method provides high encapsulation efficiencies toward hydrophilic drugs, due to their insolubility in organic solvents. However, controlling a coacervation step is quite difficult, and this method requires high costs of handling oils in large quantities [28].

**Oil-in-Water (o/w) emulsion solvent evaporation/ extraction**: An o/w emulsion solvent evaporation method involves the following steps: (i) Emulsification of a polymeric dispersed phase in an emulsifier-containing aqueous phase; (ii) Solvent diffusion from emulsion droplets into the aqueous phase; (iii) Solvent removal by evaporation; and (iv) Solidification of emulsion droplets into PLGA nanoparticles. Solvent evaporation is usually carried out by continuous stirring at ambient pressure, but its rate can be accelerated under reduced pressure, vacuum, or elevated temperature [29]. Methylene chloride, which has a low boiling point of 39.8 °C and negligible water solubility (1.32 wt %), is the preferred solvent of choice. This technique is particularly useful for loading hydrophobic drugs into PLGA nanoparticles. Prior to emulsification, an emulsifier is added to a continuous phase and/or a PLGA organic solution. Common examples of surfactants and/or stabilizers are polyvinyl alcohol (PVA), didodecylmethylammonium bromide, polyvinyl pyrrolidone, sotol, polysorbate, poloxamer, carbopol, polyethylene glycol (PEG), sodium dodecyl sulfate, proteins, carbohydrates, lecithin, and PEG-lipid (e.g., PEG-ceramide, 1-d-a-tocopheryl polyethylene glycol 1000 succinate (TPGS). It is important to notice that the type and concentration of surfactant affect the nanoparticle quality, drug encapsulation efficiency, drug release, pharmacokinetics, and cellular uptake/interaction. Therefore, a surfactant should be selected in consideration of the intended functionality and quality of PLGA nanoparticles. In the practice of solvent extraction, an excessive amount of a quench liquid (i.e., water) is added into the o/w emulsion, in order to facilitate the quenching of the dispersed organic solvent into the aqueous phase. The amount of water used for solvent extraction usually exceeds at least 10 times the theoretical amount required for saturating water with the organic solvent. Ethyl acetate with a significant water miscibility (~8 wt %) is frequently used with this nanoencapsulation method. Solvent evaporation is often hybridized with solvent extraction to effectively remove organicsolvents. Other treatments (e.g., dialysis, diafiltration/ultrafiltration, vacuum, and/or cosolvent treatment) are performed too. Table 1 summarizes experimental conditions used for nanoencapsulation of hydrophobic drugs and the major properties of PLGA nanoparticles. Important process parameters are PLGA, solvent, drug concentration, drug-polymer ratio, surfactant/emulsifier, mixing device, organic phase-continuous phase ratio, solvent removal (method and rate), and freeze-drying condition (method and lyoprotectant) [19,30-32].

**Oil-in-Oil (o1/o2) emulsion solvent evaporation/ extraction**: A PLGA/drug/organic solvent dispersed phase (o1) is emulsified in a continuous oil phase (e.g., silicone oil, liquid paraffin, or vegetable oil; o2), and the process of solvent removal is carried out as mentioned earlier. Following this principle, Mahdavi, et al. emulsified a PLGA/acetoniitrile dispersed phase (o1) in mineral oil (o2) [33]. After solvent removal, PLGA nanoparticles were recovered by centrifugation and washed by n-hexane to eliminate residual mineral oil. The mean diameters and production yield of their nanoparticles were 640~890 nm and 38.5~45.3%, respectively. Kashi, et al. dissolved PLGA and minocycline in acetoniitrile and emulsified the dispersed phase in Span 80-containing mineral oil [34]. The resulting nanoemulsion was continuously stirred in 55 °C for 2 hr to remove acetoniitrile by evaporation. Nanoparticles were collected by centrifugation and washed with n-hexane.

**Oil-in-Water (o/w) salting-out technique**: This technique involves the emulsification of a polymeric, drug containing organic solution into an electrolyte-saturated aqueous solution. A water-miscible organic solvent is used as a dispersed solvent for PLGA [35]. When a polymeric dispersed phase is mixed with an aqueous phase saturated with electrolytes, the salting-out effect prevents the mixing of the organic solvent with water, thereby producing a stable o/w emulsion. A reverse salting-out effect is induced by adding an excessive amount of water to this emulsion. This triggers the diffusion of the water-miscible solvent out of emulsion droplets into the aqueous phase, which leads to formation of nanoparticles. Examples of electrolytes used in the salting-out process are magnesium acetate, magnesium chloride, calcium chloride, and sodium chloride. Benefits of this nanoencapsulation method include the use of non-halogenated solvents to dissolve PLGA.

**Water-in-Oil-in-Water (w1/o/w2) emulsion solvent evaporation/ extraction**: This method is used to encapsulate hydrophilic drugs into PLGA nanoparticles. A hydrophilic drug is dissolved in water (w1), while PLGA is dissolved in Moderate encapsulation efficiency of 51.2% was attained with this nanoencapsulation method [36,37].

**Nano-precipitation**

When oil dissolved in a water-miscible organic solvent
is mixed with a large amount of water, spontaneous emulsification takes place to make a kinetically stable nanoemulsion. This so-called Ouzo effect is a process by which hydrophobic solutes are dispersed in water as Nano sized droplets or particles [38]. When the Ouzo emulsification process is applied for preparing polymeric nanoparticles, the nanoencapsulation method is referred to as nanoprecipitation. In this practice, a hydrophobic polymer material is first dissolved in a water miscible solvent. This polymeric dispersed phase is mixed with an aqueous phase by use of a low-energy mixing device. The solution resulting from the mixing of the polymeric phase with anti-solvent (i.e., water) is a non-solvent for the polymer solutes. As a consequence, hydrophobic polymer solutes become aggregated to form Nano sized particles. When Fessi, et al. used this nano-precipitation technique to prepare PLGA nanoparticles, they named it spontaneous displacement method [39,40].

**Spontaneous emulsion solvent diffusion (SESD) technique**

Strictly speaking, nanoprecipitation is a single-step formation of polymeric dispersion in water. In the field of the preparation of PLGA nanoparticles, this method has been slightly modified to include the steps of emulsion formation and nanoparticle hardening. Based on this strategy, Niwa, et al. proposed the so-called SESD technique [41,42]. Its key strategy was to use a binary solvent mixture consisting of water-immiscible and water-miscible solvents (e.g., methylene chloride-acetone). Ibrahim, et al. also used a methylene chloride-acetone binary system to prepare celecoxib-loaded. PLGA nanoparticles. Acetone, which is miscible with methylene chloride and water, helps decrease the interfacial tension between methylene chloride and water [43]. Additionally, the interfacial turbulence caused by the rapid diffusion of acetone from emulsion droplets to water contribute to the spontaneous breakups of emulsion droplets into Nano sized ones. Solvent evaporation follows to remove methylene chloride from the Nanoemulsion, so as to produce solid PLGA nanoparticles. These are the underlying principles of the SESD technique. On the basis of these considerations, SESD can be regarded as a hybrid of emulsion solvent evaporation/extraction and Nanoprecipitation. There are other reports that exploit the importance of a solvent system for manipulating the physicochemical attributes of resultant nanoparticles [44,45].

**Membrane emulsification technique**

Nakashima, et al. proposed the shirasu porous glass (SPG) membrane-emulsification technique to prepare various kinds of particulate matters [46,47]. Since then, this technique has been widely explored for the preparation of liposomes, micro particles, and Nanoemulsions [48]. Briefly, this emulsification system forces a polymeric dispersed phase to permeate through a porous membrane into an aqueous continuous phase. The resultant emulsion is subject to the process of solvent removal, thereby generating nanoparticles. The membrane properties (pore size, spatial distribution, and tortuosity) play a decisive role on the size of the emulsion droplets and/or nanoparticles. This feature is distinctive from other emulsification systems using high-energy sonicators, high-shear rotor/stator homogenizers, or high-pressure micro fluidizers. While these conventional mechanical methods require high energy input (106-108 J⋅m³), the membrane emulsification method uses relatively low energy input (104-106 J⋅m³). For membrane emulsification, either a polymeric dispersed phase or a premix (i.e., a ready-made coarse emulsion) is passed through a membrane. For example, Wei, et al. emulsified a PLGA dispersed phase in an aqueous phase by using a low-speed rotor/stator homogenizer [49]. This coarse emulsion had large droplet sizes with a broad size distribution. By extruding the premix through a SPG membrane (1.2~9 μm pore size) by use of nitrogen gas pressure, they were able to produce uniform PLGA nanoparticles. Yu, et al. also encapsulated docetaxel into PLGA-TPGS nanoparticles by combining preemulsification and SPG membrane emulsification [50].

**Hydrophobic ion pairing-(HIP-) and reverse micelle-hybridized o/w emulsion technique**

A number of attempts have been made to increase the loading efficiency of hydrophilic drugs into PLGA nanoparticles. One relevant strategy is to enhance the lip solubility of water-soluble drugs by use of a hydrophobic ion pairing (HIP) technique [51]. Briefly, bis (2-hylhexyl) sulfosuccinate sodium salt (AOT) was dissolved in methylene chloride, which was then vigorously stirred in an aqueous gentamicin sulfate solution. This caused a complexation reaction between the anionic AOT and the cationic gentamicin. The hydrophobic ion complex, after being recovered from the organic phase by evaporation, was used for an o/w emulsion Nanoencapsulation process [52].

**Reverse micellar method**

In this method, an aqueous solution of chitosan is added to an organic solvent containing a surfactant. Agitation is done simultaneously. Water is added to maintain the mixture in an optically transparent microemulsion phase. The amount of water is increased to obtain NPs of larger size as shown in Figure 1. Chitosan NPs prepared by this method have been used for encapsulation of doxorubicinextran conjugate [37].

**Ionic gelatin cross linked method**

In this method ionic cross-linking is achieved by aggregation of chitosan or its derivatives with oppositely charged macromolecules or in the presence...
of ionic crosslinking agent. Tripolyphosphate is the most commonly used cross-linking agent. There is a formation of gels due to ionic linkage, therefore this method is also known as ionic-gelation method [53,54] (Figure 2).

**Covalent cross linking method**

In this method there is formation of covalent bonds between chitosan or its derivatives and the functional cross-linking agent. Commonly used agents include polyethylene glycol, glutaraldehyde or monofunctional agents [55].

**Reverse micellar method**

In this method, an aqueous solution of chitosan is added to an organic solvent containing a surfactant. Agitation is done simultaneously. Water is added to maintain the mixture in an optically transparent microemulsion phase. The amount of water is increased to obtain NPs of larger size [56,57].

**Emulsion-droplet coalescence method**

This method was developed by Tokumitsu, et al. It is based on the principle of emulsion cross-linking and precipitation. In this method, two emulsions are prepared, one containing aqueous solution of chitosan and drug in liquid paraffin oil and the other containing aqueous chitosan solution of NaOH in liquid paraffin oil. Both the emulsions are mixed under high speed stirring and there will be formation of droplets which would collide and coalesce, thereby precipitating chitosan droplets to give small size particles. This method was used to prepare gadopentetic acid-loaded chitosan NPs [58].

**Nanoparticle Characterization**

Nanoparticles are generally characterized by their size, morphology and surface charge, using different techniques.

**Size of nanocarriers**

There are several tools for determining the size of nanoparticles as discussed below.

**Dynamic light scattering:** One technique that is widely used in size determination of PNPs in solution is dynamic light scattering (DLS), which is also known as photon correlation spectroscopy (PCS). In a DLS experiment, a colloidal suspension is illuminated by a monochromatic laser light that is scattered into a photon detector [59]. Due to the Brownian motion of the particles, the detected scattered light intensity fluctuates in time, and this is related to the particle size with the help of an autocorrelation function [60]. Based on the Stokes-Einstein equation the hydrodynamic diameter can be obtained. For spherical particles the relation is as follows:

\[
D_h = \frac{1}{4} \frac{k_B T}{3 \pi \eta D_t}
\]

where \(D_h\) is the hydrodynamic diameter, \(\eta\) is the relative viscosity of the solvent, \(k_B\) is the Boltzmann’s constant, \(T\) is the temperature and \(D_t\) is the translational diffusion coefficient (this is what is measured by DLS). One of the major advantages of DLS is that it provides information about the whole particulate population in short experiment duration. However, it has limited utility in determining the particle shape because DLS presumes all the particles being spherical in nature. Furthermore, as larger particles scatter more light than smaller ones, even small amounts of aggregates or dust particles could shift the particle size distribution to larger values.
Therefore, one should be cautious when interpreting size information from DLS experiments. The nanoparticle size reported is usually the intensity-based diameter (Z-average) which is the value obtained directly from the correlation function. This can be converted by Mie theory to a volume or number distribution if there is no error in the intensity distribution. When comparing size results obtained by microscopy techniques, these are number based metrologies, the corresponding size distribution for comparison is the number distribution. The DLS results should be supplemented with an imaging technique like AFM or SEM, which is helpful in resolving ambiguities associated with both techniques. For example, Sant and coworkers prepared PEG-g-PLA nanoparticles by the emulsification solvent evaporation method [61].

Morphology of nanocarriers

The size and morphology of nanocarriers exert a profound influence on the physical and chemical properties that determine their interaction with the environment and biological systems. There are certain techniques to analyze the morphology of nanoparticles. Microscopic techniques like SEM, TEM and AFM, along with particle size also determine other parameters like morphology or surface roughness of the nanoparticles [62].

Scanning electron microscope: For SEM characterization, nanoparticles dispersion should be first converted into a dry powder, which is then mounted on a sample holder followed by coating with a conductive metal, such as gold, using a sputter coater. The sample is then scanned with a focused fine beam of electrons. The surface characteristics of the sample are obtained from the secondary electrons emitted from the sample surface. The nanoparticles must be able to withstand vacuum, and the electron beam can damage the polymer [63].

Transmission electron microscope: TEM operates on different principles than SEM, yet it often brings the same type of data. The nanoparticles dispersion is deposited onto support grids or films. To make nanoparticles withstand the instrument vacuum and facilitate handling, they are fixed using either a negative staining material, such as phosphotungstic acid or derivatives, uranyl acetate, etc., or by plastic embedding. Alternative method is to expose the sample to liquid nitrogen temperatures after embedding in vitreous ice [64]. The surface characteristics of the sample are obtained when a beam of electrons is transmitted through an ultra thin sample, interacting with the sample as it passes through.

Atomic force microscopy: AFM is yet another tool used to characterize variety of surfaces, including nanoparticles, at the atomic level and it is one of the primary forms of scanning probe microscopes [65]. The prime advantage of AFM is its ability to image non-conducting samples without any specific treatment, thus allowing imaging of delicate biological and polymeric nano and microstructures. AFM requires minimal sample preparation and can be performed in ambient conditions [66]. Scanning with a sharp probe across its surface and then monitoring and compiling the tip-sample interactions provide the images of the sample surface.

Stability of nanocarriers

The colloidal stability is analyzed through zeta potential of nanocarriers. This potential is an indirect measure of the charge. It corresponds to the potential difference between the outer Helmholtz plane and the surface of shear. Laser Doppler anemometry is the technique used to measure the zeta potential. It is based on the evaluation of the velocity of particles by the shift caused in the interference fringe, which is produced by the intersection of two laser beams. The electrophoresis mobility is then transformed into zeta potential. Most colloidal particles have negative zeta potential values ranging from about -100 to -5 mV. Surface charges prevent the agglomeration of nanoparticles polymer dispersions because of strong electrostatic repulsion, thereby enhancing the stability of the nanoparticles. The zeta potential can also provide information regarding the nature of material encapsulated within the nanocapsule or coated onto the surface [67].

Particle structure

Analysis of structural changes of the free protein sample and protein nanoparticles is imperative to understand the nature of modifications taking place in the protein in terms of confirmation, folding, chemical bonding, etc., during the synthesis of nanoparticles.

X-ray diffraction: One of the techniques for this purpose is X-ray diffraction (XRD) which is the primary tool for investigating the structure of crystalline materials, from atomic arrangement to crystallite size and imperfections. XRD also analyzes the phase composition, crystallite size and shape, lattice distortions and faulting, composition variations, orientation and in situ structure development of the nanoparticles. Usually, the XRD pattern is obtained by illuminating the sample with an x-ray source (Copper Ka line) with wavelength of 1.54Å and scanning the diffraction within a certain range of the angle 2θ [68].

Fourier transform infrared spectroscopy: Another technique to supplement XRD is Fourier transform infrared spectroscopy (FTIR). The advantage of FTIR over crystallographic techniques is its capability to provide information about the structural details with greater spatial and temporal resolution [64]. The sample used for characterization is usually lyophilized nanoparticles in minute quantities. The basic principle that governs is that the bonds and groups of bonds vibrate at
characteristic frequencies. A molecule that is exposed to infrared rays absorb infrared energy at frequencies which are characteristic of that molecule. FTIR analysis is carried out by illuminating the sample with a modulated IR beam. The sample transmittance and reflectance of the infrared rays at different frequencies is translated into an IR absorption plot, which is then analyzed and matched with known signatures of identified materials in the FTIR library [69, 70].

**Importance of Nanoparticles**

Chitosan NPs have numerous applications in pharmaceutical, biological and medical discipline.

**Pulmonary drug delivery**

Drug delivery to the lungs has various advantages such as rapid and sustained drug delivery, high efficacy, no first pass metabolism and both local and systemic effects can be achieved. The factors which contribute to the enhanced drug delivery via lungs are large surface area of lungs, thin absorption barrier and high vascularity [71]. Islam and Ferro in their review claimed that drug delivery to the lungs can also be achieved by chitosan-based NPs. The positive charge of the Chitosan provides it mucoadhesive properties which increases potential for drug absorption and this positive charge also open the tight junctions which lead to an increased uptake. Chitosan also possesses antibacterial properties which provide an additional benefit of fighting the pulmonary bacterial infections [72]. The effects of various drugs have been improved with the help of Chitosan. Using Chitosan as a polymer a nanoparticles dry powder inhalation of rifampicin, an anti-tubercular drug, was formulated. This formulation has shown sustained drug release until 24 hour and no toxic effects were shown to both the cell and organ [73, 74]. Jafarinejad, et al. developed chitosan NPs for the pulmonary delivery of itraconazole (anti-fungal drug) as a dry powder formulation due to its low solubility when administered orally. This resulted in an increased pulmonary deposition of itraconazole. Petkar, et al. developed octanoyl chitosan NPs loaded with rifampicin for pulmonary delivery. This development improved sustained release and stability of rifampicin [75]. Debnath, et al. administered prothionamide (antitubercular drug) in the form of nanoparticle via pulmonary route and these NPs were coated with chitosan. This modification improved the residence time of the drug in the lungs [76].

**Nasal drug delivery**

Nasal delivery is a non-invasive technique through which, the delivered drugs reach the brain, the respiratory system and/or the systemic circulation. Chitosan increases the permeability of the hydrophilic drugs, nucleic acids, proteins and peptides across the nasal epithelium as they pose difficulty due to their low permeability [77, 78]. Chitosan has been widely used for mucosal and systemic vaccine delivery and also in preparation of DNA mucosal vaccines. It is used in mucosal vaccine delivery as it promotes absorption which enhances mucosal immune response [79, 80].

**Vaccine delivery**

Chitosan has been widely used for mucosal and systemic vaccine delivery and also in preparation of DNA mucosal vaccines. It is used in mucosal vaccine delivery as it promotes absorption which enhances mucosal immune response [81]. Mainly, the vaccine administered through oral route requires the use of NPs. Nasal route vaccines are also there. In oral delivery vaccine the main target are Peyer’s patches. Due to the nanoparticle system, the vaccine is protected from enzymatic degradation while going to the mucosal tissue and taken up by the M-cells. On the other hand, the nasal administered vaccines remain in the nasal cavity for about 15 minutes only; have to be transported over a very small distance and to be protected from low pH and enzymatic degradation [82-86]. Chitosan vaccines containing influenza, diphtheria and pertussis antigens for nasal delivery were prepared by Illum, et al. In systemic vaccine delivery, chitosan acts as an adjuvant. Activation of macrophages occurs after the uptake of chitosan [87-89]. Chitosan has been widely used for DNA mucosal vaccines. Illum, et al. developed a chitosan-based DNA flu vaccine. Incorporation of plasmid pCMVARah2 encoding peanut allergen gene into chitosan NPs showed good antigen expression and good protection after oral administration in mice. Vaccine [90, 91].

**Challenges to Product Development of Nanoparticles**

On a laboratory scale, there are various options available for the preparation of PLGA nanoparticles by emulsion based technology platforms. Different nano-encapsulation methods lead to the formation of PLGA nanoparticles with different qualities. Key aspects discussed from the manufacturing perspective are size uniformity of nanoparticle populations, drug encapsulation efficiency, mixing device, solvent type, solvent residue in nanoparticles, and mixing device. Other foremost considerations that should be given to product development include scalability of a nanoencapsulation process, reproducibility, nanoparticle characterization, and quality control. Also considered as formidable hurdles are modulating nanoparticle functionality, programmability and target ability; adjusting drug release rate with minimal burst; and correlating in vitro - in vivo behavior of nanoparticles. Relevant issues have been well discussed elsewhere [92, 93].

**Summary and Conclusions**

Nanoparticles are effective in drug delivery and also...
enhance the therapeutic efficacy of the drugs. Their positive charge makes them helpful in pulmonary drug delivery. They increase the permeability of various drugs making them available for nasal delivery. They act as an adjuvant in vaccine delivery. Overall, these applications of NPs are due to its physicochemical properties. These include biocompatibility, biodegradability, mucoadhesive character, absorption enhancing capability and in situ gelling property. However, a critical examination regarding the toxicity and safety issues of chitosan NPs and its manufacturing technique need to be investigated very closely.

Even though PLGA nanoparticles have already demonstrated great potentials as drug carriers, many overwhelming tasks still remain to be solved for their clinical translation. Before rushing into the investigation of in vivo behaviors of PLGA nanoparticles, it is imperative to make an in-depth assessment of technological aspects of a nanoencapsulation method of choice. It is also critical to carefully assess the quality of nanoparticles. In the practice of general emulsion-templated nanoencapsulation processes, mixing devices create zones of energy density in which high pressure, shear, turbulence, and/or cavitation drive the breakups of large emulsion droplets into nanosized ones. High-energy, high-shear, and high-pressure mixing devices damage the structural integrity of fragile macromolecules. Preparing PLGA nanoparticles with high loads of hydrophilic drugs often remains challenging. In addition, the mixing of a polymeric dispersed phase with antisolvent follows a bulk process, which lacks the ability to precisely direct the process of emulsification and the rate of PLGA precipitation. As a result, this procedure gives rise to the formation of a heterogeneous nanoparticle population with regard to mean diameter, size distribution, morphology, and drug content. Therefore, selecting or developing a nanoencapsulation method must surmount the aforementioned obstacles. At the same time, the nanoencapsulation method should be able to produce nanoparticles that meet the desired standards in a consistent manner.

References

1. WHO (2016) Global Tuberculosis report. World Health Organization, Geneva, Switzerland.
2. Zumla A, Chakaya J, Centis R, D’Ambrosio L, Mwaba P, et al. (2015) Tuberculosis treatment and management: an update on treatment regimens, trials, new drugs, and adjunct therapies. Lancet Respir Med 3: 220-234.
3. Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, et al. (2016) Tuberculosis. Nat Rev Dis Primers 2: 16076.
4. Dutta NK, Karakousis PC (2014) Latent tuberculosis infection: Myths, models, and molecular mechanisms. Microbiol Mol Biol Rev 78: 343-371.
5. Getahun H, Matteellli A, Chaisson RE, Raviglione M (2015) Latent mycobacterium tuberculosis infection. N Engl J Med 372: 2127-2135.
6. Kahwati LC, Feltner C, Haltern M, Woodell CL, Boland E, et al. (2016) Primary care screening and treatment for latent tuberculosis infection in adults: Evidence report and systematic review for the US Preventive Services Task Force. JAMA 316: 970-983.
7. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, et al. (2012) Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 366: 2151-2160.
8. Diacon AH, Pym A, Grobusch MP, De Los Rios JM, Gotuzzo E, et al. (2014) Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 371: 723-732.
9. Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, et al. (2013) Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 41: 1393-1400.
10. Fox W, Ellard GA, Mitchison DA (1999) Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 3: S231-S279.
11. Caminero JA (2013) Guidelines for clinical and operational management of drug-resistant tuberculosis. International Union Against Tuberculosis and Lung Disease, Paris, France.
12. Caminero JA, Matteelli A, Lange C (2012) Treatment of TB. In: Lange C, Migliori GB, Tuberculosis (ERS Monograph). European Respiratory Society, Sheffield, 154-166.
13. WHO (2006) Guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization, Geneva.
14. WHO (2008) Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. World Health Organization, Geneva.
15. WHO (2014) Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization, Geneva.
16. Falzon D, Jaramillo E, Schüinemann HJ, Arentz M, Bauer M, et al. (2011) WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 38: 516-528.
17. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, et al. (2009) The diaryquinolone TMC207 for multidrug-resistant tuberculosis. N Engl J Med 361: 2397-2405.
18. Caminero JA, Solgiu G, Zumla A, Migliori GB (2010) Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 10: 621-629.
19. Kumar R, Troiano G, Ramstack JM, Herbert P, Figu M (2012) Coacervation process. European Patent EP 2131815.
20. Bawa R (2008) Nanoparticle-based therapeutics in humans: A survey. Nanotechnology Law and Business 5: 135-155.
21. Chan JM, Valencia PM, Zhang L, Langer R, Farokhzad OC (2010) Polymeric nanoparticles for drug delivery. Methods Mol Biol 624: 163-175.
22. Griffiths G, Nystrom B, Sable SB, Khuller GK (2010) Nanobead-based interventions for the treatment and prevention of tuberculosis. Nat Rev Microbiol 8: 827-834.
23. Sosnik A, Carcaboso AM, Glisoni RJ, Moretton MA, Chiappetta DA (2010) New old challenges in tuberculosis: Potentially effective nanotechnologies in drug delivery. Adv Drug Deliv Rev 62: 547-559.
24. Kreuter J (2004) Nanoparticles as drug delivery system. Encyclopedia of Nanoscience and Nanotechnology, American Scientific Publishers, New York, NY, USA, 7: 161-180.

25. Muller RH, Mehrert W, Lucks JS (1995) Solid lipid nanoparticles (SLN) - an alternative colloidal carrier system for controlled drug delivery. European Journal of Pharmaceutics and Biopharmaceutics 41: 62-69.

26. Wissing SA, Kayser O, Muller RH (2004) Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56: 1257-1272.

27. Reis CP, Neufeld RJ, Ribeiro AJ, Veiga F (2006) Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine 2: 8-21.

28. Almouazena E, Bourgeois S, Boussaïd A, Valot P, Malleval C, et al. (2012) Development of a nanoparticle-based system for the delivery of retinoic acid into macrophages, Int J Pharm 430: 207-215.

29. Chen YL (2008) Preparation and characterization of water-soluble chitosan gel for skin hydration. European Journal of Pharmaceutics and Biopharmaceutics 1: 321-335.

30. Shadab M, Shalini G, Sana F, Saurabh S (2015) Nanotechnology as carriers for chemotherapeutics: Future of drug delivery, World Journal of Pharmaceutical Research 4: 923-946.

31. Saleem IY, Vordermeier M, Barral E, Coomes AGA (2005) Improving peptide based assay to differentiate between vaccination and mycobacterium bovis infection in cattle using nanoparticle carriers for adsorbed antigens. J Control Release 102: 551-561.

32. Shalini G, Saurabh S, Irfan A (2013) In-vitro dissolution enhancement by development of immediate release drug delivery system of rosuvastatin calcium 10 mg tablets. International Research Journal of Humanities Engineering & Pharmaceutical Sciences 4: 6-14.

33. Mahdavi H, Mirzadeh H, Hamishehkar H, Jamshidi A, Fakhari A, et al. (2010) The effect of process parameters on the size and morphology of poly (D,L-lactide-co-glycolide) micro/nanoparticles prepared by an oil in oil emulsion/ solvent evaporation technique. Journal of Applied Polymer Science 116: 528-534.

34. Kashi TSJ, Eskandarion S, Esfandyari-Manesh M, Marashi SMA, Samadi N, et al. (2012) Improved drug loading and antibacterial activity of minocycline-loaded PLGA nanoparticles prepared by solid/oil/water ion pairing method. Int J Nanomedicine 7: 221-234.

35. Wang B, Gou M, Zheng X, Wei X, Gong C, et al. (2010) Co-delivery honokiol and doxorubicin in MPEG-PLA nanoparticles. J Nanosci Nanotechnol 10: 4166-4172.

36. Konan YN, Goumy R, Allemann E (2002) Preparation and characterization of sterile and freeze-dried sub-200 nm nanoparticles. Int J Pharm 233: 239-252.

37. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM (2004) Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Release 100: 5-28.

38. Francois G, Katz JL (2005) Nanoparticles and nanocapsules created using the Ouzo effect: Spontaneous emulsification as an alternative to ultrasonic and high-shear devices. Chemphyschem 6: 209-216.

39. Fessi H, Puisieux F, Devisaguet JP, Ammoury N, Benita S (1989) Nanocapsule formation by interfacial polymer deposition following solvent displacement. International Journal of Pharmaceutics 55: 1-4.

40. Huang J, Zhang H, Yu Y, Chen Y, Wang D, et al. (2014) Biodegradable self-assembled nanoparticles of poly (D,L-lactide-co-glycolide)/hyaluronic acid block copolymers for target delivery of docetaxel to breast cancer. Biomaterials 35: 550-566.

41. Dinavand R, Sepehri N, Manoochehri S, Atyabi F (2011) Poly(lactide-co-glycolide) nanoparticles for controlled delivery of anticancer agents. Int J Nanomedicine 6: 877-895.

42. Vitale SA, Katz JL (2003) Liquid droplet dispersions formed by homogeneous liquid-liquid nucleation: ‘The Ouzo effect’. Langmuir 19: 4105-4110.

43. Niwa T, Takeuchi H, Hino T, Kunou N, Kawashima Y (1993) Preparations of biodegradable nanospheres of water-soluble and insoluble drugs with D,L-lactide/glycolide copolymer by a novel spontaneous emulsification solvent diffusion method, and the drug release behavior. Journal of Controlled Release 25: 89-98.

44. El-Shabouri MH (2002) Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. Int J Pharm 249: 101-108.

45. Murakami H, Kobayashi M, Takeuchi H, Kawashima Y (1999) Preparation of poly (D,L-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method. Int J Pharm 187: 143-152.

46. Nakashima T, Shimizu M, Kukizaki M (1992) Membrane emulsification by microporous glass. Key Engineering Materials 61-62: 513-516.

47. Nakashima T, Shimizu M, Kukizaki M (2000) Particle control of emulsion by membrane emulsification and its applications. Adv Drug Deliv Rev 45: 47-56.

48. Charcosset C, Limayem I, Fessi H (2004) The membrane emulsification process - a review. Journal of Chemical Technology and Biotechnology 79: 209-218.

49. Wei Q, Wei W, Lai B, Wang LY, Wang YX, et al. (2008) Uniform-sized PLA nanoparticles: Preparation by premix membrane emulsification. Int J Pharm 359: 294-297.

50. Yu Y, Tan S, Zhao S, Zhuang X, Song Q, Wang Y, et al. (2013) Antitumor activity of docetaxel-loaded polymeric nanoparticles fabricated by Shirasu porous glass membrane-emulsification technique. Int J Nanomedicine 8: 2641-2652.

51. Imbuluzqueta E, Elizondo E, Gamazo C, Moreno-Calvo E, Veciana J, et al. (2011) Novel bioactive hydrophobic gentamicin carriers for the treatment of intracellular bacterial infections. Acta Biomater 7: 1599-1608.

52. Imbuluzqueta E, Gamazo C, Lana H, Campanero MA, Salas D, et al. (2013) Hydrophobic gentamicin-loaded nanoparticles are effective against Brucella melitensis infection in mice. Antimicrob Agents Chemother 57: 3326-3333.

53. Nagpal K, Singh SK, Mishra DN (2010) Chitosan nanoparticles: A promising system in novel drug delivery. Chem Pharm Bull (Tokyo) 58: 1423-1430.

54. Soutter W (2013) Chitosan nanoparticles - properties and applications. AZO Nano.

55. Mohammed MA, Syeda JTM, Wasan KM, Wasan EK (2017) An overview of chitosan nanoparticles and its application in non-parenteral drug delivery. Pharmaceutica 9: 53.

56. Avadi MR, Sadeghi AMM, Mohammadpour N, Abedin S, Atyabi F, et al. (2010) Preparation and characterization of insulin nanoparticles using chitosan and Arabic gum with ionic gelation method. Nanomedicine 6: 58-63.
57. Prabaharan M, Mano JF (2005) Chitosan-based particles as controlled drug delivery systems. Drug Deliv 12: 41-57.
58. Tokumitsu H, Ichikawa H, Fukumori Y (1999) Chitosan-gadopentetic acid complex nanoparticles for gadolinium neutron-capture therapy of cancer: Preparation by novel emulsion-droplet coalescence technique and characterization. Pharm Res 16: 1830-1835.
59. Kaszuba M, McKnight D, Connah MT, McNeil-Watson FK, Nobbmann U (2008) Measuring sub nanometre sizes using dynamic light scattering. J Nanopart Res 10: 823-829.
60. Lim J, Yea SP, Che HX, Low SC (2013) Characterization of magnetic nanoparticle by dynamic light scattering, Nanoscale Res Lett 8: 381.
61. Sant S, Nadeau V, Hildgen P (2005) Effect of porosity on the release kinetics of propafenone-loaded PEG-g-PLA nanoparticles. J Control Release 107: 203-214.
62. Bera D, Qian L, Tseng TK, Holloway PH (2010) Quantum dots and their multimodal applications: A review. Materials (Basel) 3: 2260-2345.
63. Mattoussi H, Palui G, Na HB (2012) Luminescent quantum dots as platforms for probing in vitro and in vivo biological processes. Adv Drug Deliv Rev 64: 138-166.
64. Pastorin G, Wu W, Wieckowski S, Briand JP, Kostarelos K, et al. (2006) Double functionalization of carbon nanotubes for multimodal drug delivery. Chem Commun (Camb) 11: 1182-1184.
65. Bohrey S, Chourasiya V, Pandey A (2016) Polymeric nanoparticles containing diazepam: Preparation, optimization, characterization, in-vitro drug release and release kinetic study. Nano Converg 3: 3.
66. Amzallag A, Vaillant C, Jacob M, Unser M, Bednar J, et al. (2006) 3-D reconstruction and comparison of shapes of DNA minicircles observed by cryo-electron microscopy. Nucleic Acids Res 34: e125.
67. Blanchard CR (1996) Atomic force microscopy. Chem Educ 5: 1.
68. Magonov SN (1993) Surface Characterization of materials at ambient conditions by scanning tunneling microscopy and atomic force microscopy. Appl Spect Rev 28: 1.
69. Shukla SK, Jain R, Pandey A (2015) Nanosuspension formulation to improve the dissolution rate of Clonazepam. Int J Adv Res 3: 588-591.
70. Berthomieu C, Hienervadel R (2009) Fourier transform infrared (FTIR) spectroscopy. Photosynth Res 101: 157-170.
71. Ruge CA, Kirch J, Lehr CM (2013) Pulmonary drug delivery: From generating aerosols to overcoming biological barriers-therapeutic possibilities and technological challenges. Lancet Respir Med 1: 402-413.
72. Islam N, Ferro V (2016) Recent advances in chitosan-based nanoparticulate pulmonary drug delivery. Nanoscale 8: 14341-14358.
73. Rawal T, Parmar R, Tyagi RK, Butani S (2017) Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis. Colloids Surf B Biointerfaces 154: 321-330.
74. Jafarinejad S, Gilani K, Moazeni E, Ghazi-Khansari M, Najafabadi AR, et al. (2012) Development of chitosan-based nanoparticles for pulmonary delivery of itraconazole as dry powder formulation. Powder Technology 222: 65-70.
75. Debnath SK, Saisivam S, Debanth M, Omri A (2018) Development and evaluation of Chitosan nanoparticles based dry powder inhalation formulations of Prothioamide. PLoS One 13: e0190976.
76. Deacon MP, McGurk S, Roberts CJ, Williams PM, Tendler SJ, et al. (2000) Atomic force microscopy of gastric mucin and chitosan mucoadhesive systems. Biochem J 3: 557-563.
77. Dodane V, Amin Khan M, Merwin JR (1999) Effect of Chitosan on epithelial permeability and structure. Int J Pharm 182: 21-32.
78. Fang N, Chan V, Mao HQ, Leong KW (2001) Interactions of phospholipid bilayer with chitosan: Effect of molecular weight and pH. Biomacromolecules 2: 1161-1168.
79. Thanou M, Verhoef JC, Verheijden JH, Junginger HE (2001) Intestinal absorption of octreotide using trimethyl chitosan chloride: Studies in pigs. Pharm Res 18: 823-828.
80. Martirosyan A, Olesen MJ, Howard KA (2014) Chitosan-based nanoparticles for mucosal delivery of RNAi therapeutics. Adv Genet 88: 325-352.
81. Prego C, Fabre M, Torres D, Alonso MJ (2006) Efficacy and mechanism of action of chitosan nanocapsules for oral peptide delivery. Pharm Res 23: 549-556.
82. Colonna C, Dorati R, Conti B, Caliceti P, Genta I (2013) Sub-unit vaccine against S. aureus-mediated infections: Setup of nano-sized polymeric adjuvant. Int J Pharm 452: 390-401.
83. Cohen H, Levy RJ, Gao J, Fishbein I, Kousav V, et al. (2000) Sustained delivery and expression of DNA encapsulated in polymeric nanoparticles. Gene Ther 7: 1896-1905.
84. Li F, Sun J, Zhu H, Wen X, Lin C, et al. (2011) Preparation and characterization novel polymer-coated magnetic nanoparticles as carriers for doxorubicin. Colloids Surf B Biointerfaces 88: 58-62.
85. Wang M, Zhang Y, Feng J, Gu T, Dong Q, et al. (2013) Preparation, characterization, and in vitro and in vivo investigation of chitosan-coated poly (d,l-lactide-co-glycolide) nanoparticles for intestinal delivery of exendin-4. Int J Nanomedicine 8: 1141-1154.
86. Murata Y, Toniiwa S, Miyamoto E, Kawashima S (1999) Preparation of alginate gel beads containing chitosan nicotinic acid salt and the functions. Eur J Pharm Biopharm 48: 49-52.
87. Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS (2001) Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 51: 81-96.
88. Roy K, Mao HQ, Huang SK, Leong KW (1999) Oral gene delivery with chitosan--DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 5: 387-391.
89. Rajesh Kumar S, Ishaq Ahmed VP, Parameswaran V, Sudhakaran R, Sarath Babu V, et al. (2008) Potential use of chitosan nanoparticles for oral delivery of DNA vaccine in Asian sea bass (Lates calcarifer) to protect from Vibrio (Listonella) anguillarum. Fish Shellfish Immunol 25: 47-56.
90. Van der Lubben IM, Verhoef JC, Borchard G, Junginger HE (2001) Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur J Pharm Sci 14: 201-207.
91. Pawar D, Jaganathan KS (2016) Mucoadhesive glycol chitosan nanoparticles for intranasal delivery of hepatitis B vaccine: Enhancement of mucosal and systemic immune response. Drug Deliv 23: 185-194.
92. Desai N (2012) Challenges in development of nanoparticle-based therapeutics. AAPS J 14: 282-295.
93. Kaur IP, Kakkar V, Deol PK, Yadav M, Singh M, et al. (2014) Issues and concerns in nanotech product development and its commercialization. J Control Release 193: 51-62.